8/12/2020 8:07:29 AM
Vaccibody And Nektar Therapeutics Announce First Patient Dosed In Phase 1/2a Study Arm Evaluating VB10.NEO With NKTR-214
8/6/2020 4:19:35 PM
Nektar Q2 Loss/Shr $0.45 Vs Loss $0.63 Last Year
6/8/2020 8:06:23 AM
William Blair Reiterates Nektar Therapeutics (NKTR) At Outperform
5/22/2020 8:32:54 AM
Nektar Reports Publication Of Results From Phase 1 Dose-Escalation Study For Bempegaldesleukin Plus Nivolumab
2/28/2020 8:12:37 AM
William Blair Is Cutting Nektar Therapeutics (NKTR) FY22 Rev. Estimate To 108 M From 170 M
2/28/2020 8:12:22 AM
William Blair Is Cutting Nektar Therapeutics (NKTR) FY21 Rev. Estimate To 107 M From 159 M
2/28/2020 8:12:07 AM
William Blair Is Increasing Nektar Therapeutics (NKTR) FY20 Rev. Estimate To 144 M From 133 M
2/28/2020 8:11:41 AM
William Blair Is Raising Nektar Therapeutics (NKTR) FY22 Estimate To -3.55 From -3.64
2/28/2020 8:11:25 AM
William Blair Is Raising Nektar Therapeutics (NKTR) FY21 Estimate To -3.18 From -3.22
2/28/2020 8:11:07 AM
William Blair Is Increasing Nektar Therapeutics (NKTR) FY20 Estimate To -2.96 From -3.00
2/28/2020 7:57:41 AM
William Blair Reiterates Nektar Therapeutics (NKTR) At Outperform
2/27/2020 4:20:02 PM
Nektar Therapeutics Q4 Loss Per Share $0.64 Vs Loss $0.57 Last Year
2/3/2020 8:07:50 AM
Nektar Publishes Two Manuscripts On Lead Immuno-oncology Candidate, Bempegaldesleukin In Nature Communications